Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Kalinich M, Murphy W, Wongvibulsin S, Pahalyants V, Yu KH, Lu C, Wang F, Zubiri L, Naranbhai V, Gusev A, Kwatra SG, Reynolds KL, Semenov YR. Kalinich M, et al. J Immunother Cancer. 2021 Mar;9(3):e001935. doi: 10.1136/jitc-2020-001935. J Immunother Cancer. 2021. PMID: 33789879 Free PMC article.
An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer.
Miyamoto DT, Lee RJ, Kalinich M, LiCausi JA, Zheng Y, Chen T, Milner JD, Emmons E, Ho U, Broderick K, Silva E, Javaid S, Kwan TT, Hong X, Dahl DM, McGovern FJ, Efstathiou JA, Smith MR, Sequist LV, Kapur R, Wu CL, Stott SL, Ting DT, Giobbie-Hurder A, Toner M, Maheswaran S, Haber DA. Miyamoto DT, et al. Among authors: kalinich m. Cancer Discov. 2018 Mar;8(3):288-303. doi: 10.1158/2159-8290.CD-16-1406. Epub 2018 Jan 4. Cancer Discov. 2018. PMID: 29301747 Free PMC article. Clinical Trial.
Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy.
Hong X, Sullivan RJ, Kalinich M, Kwan TT, Giobbie-Hurder A, Pan S, LiCausi JA, Milner JD, Nieman LT, Wittner BS, Ho U, Chen T, Kapur R, Lawrence DP, Flaherty KT, Sequist LV, Ramaswamy S, Miyamoto DT, Lawrence M, Toner M, Isselbacher KJ, Maheswaran S, Haber DA. Hong X, et al. Among authors: kalinich m. Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2467-2472. doi: 10.1073/pnas.1719264115. Epub 2018 Feb 16. Proc Natl Acad Sci U S A. 2018. PMID: 29453278 Free PMC article.
Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.
Wongvibulsin S, Pahalyants V, Kalinich M, Murphy W, Yu KH, Wang F, Chen ST, Reynolds K, Kwatra SG, Semenov YR. Wongvibulsin S, et al. Among authors: kalinich m. J Am Acad Dermatol. 2022 Mar;86(3):563-572. doi: 10.1016/j.jaad.2021.03.094. Epub 2021 Apr 2. J Am Acad Dermatol. 2022. PMID: 33819538 Free PMC article.
A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer.
Kwan TT, Bardia A, Spring LM, Giobbie-Hurder A, Kalinich M, Dubash T, Sundaresan T, Hong X, LiCausi JA, Ho U, Silva EJ, Wittner BS, Sequist LV, Kapur R, Miyamoto DT, Toner M, Haber DA, Maheswaran S. Kwan TT, et al. Among authors: kalinich m. Cancer Discov. 2018 Oct;8(10):1286-1299. doi: 10.1158/2159-8290.CD-18-0432. Epub 2018 Aug 13. Cancer Discov. 2018. PMID: 30104333 Free PMC article.
Seroprevalence of anti-SARS-CoV-2 IgG Antibodies in the Staff of a Public School System in the Midwestern United States.
Lopez L, Nguyen T, Weber G, Kleimola K, Bereda M, Liu Y, Accorsi EK, Skates SJ, Santa Maria JP Jr, Smith KR, Kalinich M. Lopez L, et al. Among authors: kalinich m. medRxiv [Preprint]. 2020 Oct 27:2020.10.23.20218651. doi: 10.1101/2020.10.23.20218651. medRxiv. 2020. Update in: PLoS One. 2021 Jun 10;16(6):e0243676. doi: 10.1371/journal.pone.0243676. PMID: 33140066 Free PMC article. Updated. Preprint.
19 results